London
· Delayed Price · Currency is GBP · Price in USD Alnylam Pharmaceuticals Statistics
Total Valuation
LON:0HD2 has a market cap or net worth of GBP 26.85 billion. The enterprise value is 26.88 billion.
| Market Cap | 26.85B |
| Enterprise Value | 26.88B |
Important Dates
The next estimated earnings date is Thursday, May 1, 2025.
| Earnings Date | May 1, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +2.20% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 124.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | 500.98 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -121.00 |
| EV / Sales | 15.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -790.28 |
Financial Position
The company has a current ratio of 2.78, with a Debt / Equity ratio of 40.89.
| Current Ratio | 2.78 |
| Quick Ratio | 2.61 |
| Debt / Equity | 40.89 |
| Debt / EBITDA | n/a |
| Debt / FCF | -64.42 |
| Interest Coverage | -1.25 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -2.74% |
| Return on Invested Capital (ROIC) | -4.19% |
| Return on Capital Employed (ROCE) | -5.79% |
| Revenue Per Employee | 805,305 |
| Profits Per Employee | -99,634 |
| Employee Count | 2,230 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 3.86 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +76.49% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +76.49% |
| 50-Day Moving Average | 259.59 |
| 200-Day Moving Average | 255.58 |
| Relative Strength Index (RSI) | 55.68 |
| Average Volume (20 Days) | 611 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 3.26 |
Income Statement
In the last 12 months, LON:0HD2 had revenue of GBP 1.80 billion and -222.18 million in losses. Loss per share was -1.74.
| Revenue | 1.80B |
| Gross Profit | 1.54B |
| Operating Income | -141.29M |
| Pretax Income | -301.44M |
| Net Income | -222.18M |
| EBITDA | -96.02M |
| EBIT | -141.29M |
| Loss Per Share | -1.74 |
Balance Sheet
The company has 2.15 billion in cash and 2.19 billion in debt, giving a net cash position of -39.07 million.
| Cash & Cash Equivalents | 2.15B |
| Total Debt | 2.19B |
| Net Cash | -39.07M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 53.59M |
| Book Value Per Share | 0.41 |
| Working Capital | 1.68B |
Cash Flow
In the last 12 months, operating cash flow was -6.64 million and capital expenditures -27.38 million, giving a free cash flow of -34.02 million.
| Operating Cash Flow | -6.64M |
| Capital Expenditures | -27.38M |
| Free Cash Flow | -34.02M |
| FCF Per Share | n/a |
Margins
Gross margin is 85.62%, with operating and profit margins of -7.87% and -12.37%.
| Gross Margin | 85.62% |
| Operating Margin | -7.87% |
| Pretax Margin | -16.79% |
| Profit Margin | -12.37% |
| EBITDA Margin | -5.35% |
| EBIT Margin | -7.87% |
| FCF Margin | n/a |
Dividends & Yields
LON:0HD2 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.20% |
| Shareholder Yield | -2.20% |
| Earnings Yield | -0.83% |
| FCF Yield | -0.13% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LON:0HD2 has an Altman Z-Score of 2.48. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.48 |
| Piotroski F-Score | n/a |